Q J Med 1999; 92: 211-218
© 1999 Association of Physicians
The very long-term prognosis and complications of lupus nephritis and its treatment
From the Renal Unit, UMDS Guy's and St Thomas' Hospitals, London, UK
Received 18 September 1998 and in revised form 5 February 1999
Professor J.S. Cameron, Elm Bank, Melmerby, Cumbria CA10 1HB.e-mail:jstewart_cameron{at}email.msn.com
Although the short- and medium-term (5–10 years) outcome of patients with lupus nephritis has been studied extensively, there are very few data on the second and subsequent decades. We studied outcome in 110 local patients investigated at a single centre before 1986, who all had potential follow-up of more than 10 years (actual 2–31 years, median 15.5 years). At last follow-up, 40 patients were dead and 70 alive, nine of whom were on maintenance dialysis or transplanted, actuarial survivals being 84%, 72%, 62%, 61% and 54% at 5, 10, 15, 20 and 25 years for the group as a whole. Survival was better in the cohort 1976–86 (n=60) than in that from 1963–75 (n=50) (90, 81 and 76% vs. 78, 56 and 43% at 5, 10 and 15 years, p<0.001). Sepsis (12) and myocardial infarction (8) were the principal causes of death. Of living patients with renal function, 38% had normal urine and renal function, 11 were off all treatment (19%), 62% had persistent proteinuria and 18% had reduced but generally stable renal function. Renal failure, in those patients who developed it, occurred during the first decade and none of 67 patients actually followed more than 10 years subsequently went into renal failure. Induction treatment was with prednisolone, combined with azathioprine in more severe forms of nephritis, and from the middle 1970s to 1986, 30 with methylprednisolone and in 12 cases plasma exchange. Seventeen other patients were treated using oral cyclophosphamide during the 1960s. No patient received i.v. cyclophosphamide as induction therapy, although nine patients had this form of treatment later, largely because of non-compliance. Serious complications of lupus and/or its treatment occurred in 49%: sepsis in 32, ischaemic heart disease in 20, thrombosis in one and avascular necrosis of bone in eight. In contrast, fracturing osteoporosis occurred in only three, and cataracts requiring surgery and diabetes mellitus in none. The very long-term outlook of lupus nephritis, especially its more severe forms, has improved, but that with current management strategies only a minority of patients are able to stop treatment altogether, and the incidence of serious complications is high.
* Present address: Servizio Nefrologia e Dialisi, Ospedale `G di Cristina`, Pizza Montalto, 90134 Palermo, Italy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Mok, K. Ying, C. Yim, W. Ng, and W. Wong Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine Lupus, October 1, 2009; 18(12): 1091 - 1095. [Abstract] [PDF]
|
|
|
|
 |
|
 H. A. Austin III, G. G. Illei, M. J. Braun, and J. E. Balow Randomized, Controlled Trial of Prednisone, Cyclophosphamide, and Cyclosporine in Lupus Membranous Nephropathy J. Am. Soc. Nephrol., April 1, 2009; 20(4): 901 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.O. Sun, W.X. Hu, H.L. Xie, H.T. Zhang, H.P. Chen, C.H. Zeng, Z.H. Liu, and L.S. Li Long-term outcome of Chinese patients with membranous lupus nephropathy Lupus, January 1, 2008; 17(1): 56 - 61. [Abstract] [PDF]
|
|
|
|
|
|
V Baca, T Catalan, M Villasis-Keever, G Ramon, A. Morales, and F Rodriguez-Leyva Effect of Low-Dose Cyclosporine A in the Treatment of Refractory Proteinuria in Childhood-Onset Lupus Nephritis Lupus, August 1, 2006; 15(8): 490 - 495. [Abstract] [PDF]
|
|
|
|
|
|
C C Mok Prognostic factors in lupus nephritis Lupus, January 1, 2005; 14(1): 39 - 44. [Abstract] [PDF]
|
|
|
|
|
|
H A Austin and G G Illei Membranous lupus nephritis Lupus, January 1, 2005; 14(1): 65 - 71. [Abstract] [PDF]
|
|
|
|
|
|
D Jayne and A Tyndall Autologous stem cell transplantation for systemic lupus erythematosus Lupus, May 1, 2004; 13(5): 359 - 365. [Abstract] [PDF]
|
|
|
|
|
|
P I Sidiropoulos and D T Boumpas Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients Lupus, May 1, 2004; 13(5): 391 - 397. [Abstract] [PDF]
|
|
|
|
 |
|
 C Fiehn, Y Hajjar, K Mueller, R Waldherr, A D Ho, and K Andrassy Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment Ann Rheum Dis, May 1, 2003; 62(5): 435 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. G. Illei, H. A. Austin III, M. Crane, L. Collins, M. F. Gourley, C. H. Yarboro, E. M. Vaughan, T. Kuroiwa, C. L. Danning, A. D. Steinberg, et al. Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis Ann Intern Med, August 21, 2001; 135(4): 248 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Moroni, G. C. Greloni, and C. Ponticelli Late recurrence of lupus nephritis after long-term clinical remission Nephrol. Dial. Transplant., April 1, 2001; 16(4): 849 - 852. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Font, M. Ramos-Casals, R. Cervera, M. Garcia-Carrasco, A. Torras, A. Siso, A. Darnell, and M. Ingelmo Cardiovascular risk factors and the long-term outcome of lupus nephritis QJM, January 1, 2001; 94(1): 19 - 26. [Abstract] [Full Text] [PDF]
|
|